==== Front Evid Based Complement Alternat Med Evid Based Complement Alternat Med ECAM Evidence-based Complementary and Alternative Medicine : eCAM 1741-427X 1741-4288 Hindawi 10.1155/2020/8873371 Research Article Evidence of TCM Theory in Treating the Same Disease with Different Methods: Treatment of Pneumonia with Ephedra sinica and Scutellariae Radix as an Example https://orcid.org/0000-0002-3679-4469Sun Liping slpcczyydx@sina.com 1 Wang Dandan 2 Xu Yan 1 Qi Wenxiu 1 https://orcid.org/0000-0002-1249-0444Wang Yanbo 14463798@qq.com 1 1Changchun University of Chinese Medicine, Changchun 130117, China 2Affiliated Hospital of Changchun University of Chinese Medicine, Changchun, Jilin 130021, China Academic Editor: Chang Hong 2020 28 11 2020 28 11 2020 2020 887337110 8 2020 20 9 2020 20 10 2020 Copyright © 2020 Liping Sun et al.2020This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Pneumonia is a serious global health problem and the leading cause of mortality in children. Antibiotics are the main treatment for bacterial pneumonia, but there are serious drug resistance problems. Traditional Chinese medicine (TCM) has been used to treat diseases for thousands of years and has a unique theory. This article takes the treatment of pneumonia with Ephedra sinica as a representative hot medicine and Scutellariae Radix as a representative cold medicine as an example. We explore and explain the theory of treating the same disease with different TCM treatments. Using transcriptomics and network pharmacology methods, GO, KEGG enrichment, and PPI network construction were carried out, demonstrating that Ephedra sinica plays a therapeutic role through the NF-κB and apoptosis signaling pathways targeting PLAU, CD40LG, BLC2L1, CASP7, and CXCL8. The targets of Scutellariae Radix through the IL-17 signaling pathway are MMP9, CXCL8, and MAPK14. Molecular docking technology was also used to verify the results. In short, our results provide evidence for the theory of treating the same disease with different treatments, and we also discuss future directions for traditional Chinese medicine. National Key Research and Development Program of China2017YFC1703202Jilin Scientific and Technological of Chinese Medicine Program2019023Inheritance and Innovation of Chinese Medicine of “Millions of Standouts” Project (the Project of Qihuang)Inheritance Workroom of the Chinese Medicine Master Wang LieJilin Scientific and Technological Program of Sanitation and Population Control2018J106 ==== Body 1. Background Pneumonia is a serious global health problem [1] and the leading cause of death in children [2]; pneumonia can be caused by bacteria, viruses, fungi, and other microorganisms [3]. Antibiotics are currently the most important treatment for bacterial pneumonia and have been used for a variety of bacterial diseases. The Global Antimicrobial Resistance Surveillance System (GLASS) report released by the World Health Organization in 2019 reveals a worrying reality: the emergence and spread of antibiotic resistance worldwide has directly led to prolonged disease treatment cycles, increased complications, and even death [4, 5]. Therefore, there is an extremely urgent need to explore new methods to treat pneumonia. Traditional Chinese medicine, the most popular traditional medicine system in the world, is the traditional medicine system in China and has been guided by materialistic philosophy for thousands of years. We think that exploring new ways to use traditional Chinese medicine to treat diseases will help to improve modern medicine and support the development of new drugs. Traditional Chinese medicine (TCM) is different from modern medicine and has a unique system of preventing, diagnosing, and treating diseases based on the philosophy of naive materialism [6]. The core idea is the equilibrium state between humans and nature. Theories including Yin and Yang and the Five Elements are intended to explain this equilibrium state. When people and nature are out of balance, diseases will occur. At this time, methods such as Chinese medicine, acupuncture, tai chi, and qigong can be used to correct this imbalance [7, 8], as shown in Figure 1. Among these methods, Chinese medicine has the characteristics of four kinds of “qi.” The four qi are the four natural attributes of being very cold, cold, hot, and warm. Hot and warm are distinguished by the degree of heat, and very cold and cold are distinguished by the degree of coldness. These types of qi are used to correct different degrees of heat and coldness in the human body [9]. Most of the time, the theory of TCM has explored the method of harmonizing people with nature from the perspective of a philosophical theory. Although Chinese people take pride in the theory of TCM, there is no modern scientific evidence for its effectiveness. Since the launch of the Human Genome Project in the 1990s, large-scale research on genes and their expression products has emerged, such as genomics, transcriptomics, and proteomics, and related technologies have developed rapidly. Among them, transcriptomics can systematically detect the cell status and comprehensively reflect the real-time expression status and degree of degradation, which is extremely important for the research of human diseases. There have been many omics studies of TCM before. For example, Wu et al. studied the application of metabolomics in the treatment of coronary heart disease with TCM [10]. Zhao et al. also used metabolomics techniques to explore the anti-inflammatory effects of Zhishi and Zhiqiao [11]. Peng et al. integrated transcriptomics, proteomics, metabolomics, and systems pharmacology to explore the mechanism of the Bufei Yishen formula in treating chronic obstructive pulmonary disease [12]. However, research using omics technology to explain the theory of TCM is very rare. Only one study has been reported, in which He et al. used transcriptomics technology to discuss the blood stasis theory of TCM [13]. Many theories of Chinese medicine are the soul of Chinese medicine and the basis for guiding clinical medication. Therefore, the use of omics technology to explore TCM theory is both innovative and meaningful research. In TCM theory, both cold and hot medicines can be used to treat the same disease, which is called “treating the same disease with different treatments” [14], which means that different treatment methods are used at different stages of disease development [15]. Based on the number of studies and citations in the published literature, we selected Ephedra sinica (ES), a small shrub in the genus Ephedra, which has the function of dissipating wind-cold, freeing the lungs, and relieving asthma and is considered warm in Chinese medicine, as a representative of warm drugs. Scutellariae Radix (SR), the dry root of the Labiatae plant Scutellaria baicalensis Georgi, which has the functions of clearing heat and dampness, purging fire, and detoxifying and is considered to be cold, was chosen as a representative of cold drugs. Both drugs are believed to have therapeutic effects on pneumonia. Briefly, the aim of this study was to investigate the specific mechanisms of ES and SR, two representative Chinese medicines for the treatment of pneumonia, using network pharmacology and transcriptomics combined with animal experiments. To clarify the four types of qi in Chinese medicine and guide clinical treatment, a research schematic is shown in Figure 2. Our results suggest that ES and SR treat bacterial pneumonia via different signaling pathways and confirm the theory of treating the same disease with different methods in TCM. 2. Methods 2.1. Molecular Information and Target Sets for ES and SR The molecular information of ES and SR was obtained from the TCMSP database (http://tcmspw.com/tcmsp.php) constructed by previous researchers, and their physical and chemical properties, such as molecular weight (MW), the number of donor atoms for H-bonds (nHDon), the number of acceptor atoms for H-bonds (nHAcc), and the Moriguchi octanol–water partition coeff. (log P), were analyzed [16]. To further explain the absorption, distribution, metabolism, and excretion (ADME) process of these two drugs in the body [17], also based on previous research, the oral bioavailability (OB) and druglikeness (DL) were used as the screening conditions [18]. When OB ≥ 30% and DL ≥ 0.18, the molecule is regarded as a drug that can be absorbed by the human body. The molecular targets were also obtained through TCMSP, and information on each target was entered into UniProt (http://www.uniprot.org/) for correction. 2.2. Differentially Expressed Genes Associated with Pneumonia Differentially expressed genes associated with pneumonia were obtained from NCBI-GEO, a free publicly available microarray database. The GEO accession number is GSE103119 and includes transcriptome data for 152 children with community-acquired pneumonia (CAP) and 20 healthy controls. These data were used only because children are the main population affected by community-acquired pneumonia. Then, these data were analyzed using GEO2R online tools [19], and differentially expressed genes were screened using |logFC| > 1 and an adjusted P < 0.05 as indicators. 2.3. PPI Network and GO and KEGG Pathway Enrichment Analysis The ES and SR targets and the abovementioned differential genes are intersected. Then, the protein-protein interaction (PPI) network and Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were performed. The PPI network was analyzed using the Search Tool for the Retrieval of Interacting Genes (STRING, http://string.embl.de/) database, the minimum required interaction score is set to medium confidence (0.400), and the organism was Homo sapiens. GO enrichment can be divided into 3 main parts including biological process (BP), molecular function (MF), and cellular component (CC). Generally speaking, BP is the main direction of all gene functions in GO [20, 21], and thus, we used GO-BP for enrichment analysis. GO-BP and KEGG pathway enrichment analysis was performed using the clusterProfiler package in R(3.6.1) software, with p value cutoff = 0.05 and q value cutoff = 0.05 [22] for analysis. Network diagrams were generated with Cytoscape 3.6.0 software. 2.4. Chinese Herbs ES and SR Ephedra sinica and Scutellariae Radix were purchased from Jiangyin Tianjiang Pharmaceutical Co., Ltd. (Jiangyin, China), and the production batch numbers were 19046614 and 19086524, respectively. These two medicines are marketed prescription drugs approved by the China Food and Drug Administration and are administered as granules. 2.5. Streptococcus pneumoniae and Mouse Model Streptococcus pneumoniae strain D39 serotype 2 (NCTC 7466) was kindly provided by Professor Jian Huang from Zunyi Medical University (Zunyi, China) and cultured in Todd-Hewitt broth with 1% yeast extract (THY media) at 37°C with 5% CO2. BALB/c mice (female, 6–8 weeks old, 20–22 g) were purchased from the Liaoning Changsheng Biotechnology Co., Ltd. (Shenyang, China) and maintained in accordance with the NIH Guide for the Care and Use of Laboratory Animals. All mouse experiments were approved by the ethics committee of the Changchun University of Chinese Medicine. Streptococcus pneumoniae strain D39 was cultured until the OD600 nm reached 0.4 (midlogarithmic phase), collected by centrifugation (1000 rpm for 10 min), and washed three times with PBS. Each mouse was nasally infected with 1.5 × 108 colony-forming units (CFUs) of bacteria, except for those in the healthy control group. The mice were subcutaneously injected with ES (40 mg/kg), SR (40 mg/kg), or DMSO every 8 h, and the lungs from sacrificed mice (n = 8) were used for histopathological analysis by hematoxylin-eosin staining under light microscopy at 48 h after infection. Furthermore, other mice were used to collect bronchoalveolar lavage (BAL) fluid, and it was centrifuged. The levels of TNF-α and interleukin (IL)-6 were determined in the supernatants using mouse ELISA kits (Biolegend) according to the manufacturer's recommendations. 2.6. Molecular Docking Data for the PLAU (PDB ID: 1C5Z), CD40LG (PDB ID: 3LKJ), BCL2L1 (PDB ID: 3QKD), CASP7 (PDB ID: 1SHJ), CXCL8 (PDB ID: 1QE6), MMP9 (PDB ID: 1GKD), CXCL8 (PDB ID: 1QE6), and MAPK14 (PDB ID: 1A9U) proteins were downloaded from the PDB database (http://www.rcsb.org/). Then, Mgltools 1.5.6 was used to process the protein via hydrogenation, calculate the charge, merge the nonpolar hydrogen, and save it as a pdbqt file. According to the protein's ligand, we defined the active site, set the grid box coordinates, defined the box size as 40 × 40 × 40 grid points, and set the distance of each small grid point as 0.1 nm. AutodockVina 1.1.2 was used for the docking of molecules and proteins. An affinity of less than 0 indicated that the receptor and ligand could spontaneously bind. 2.7. Statistical Analysis Data were expressed by the mean ± SD (n ≥ 3) and analyzed by GraphPad Prism 6.0 (GraphPad Software) using the Student's t-test; ∗∗p < 0.01. 3. Results 3.1. ES and SR Can Treat Pneumonia in Mice To evaluate the antimicrobial effect of ES and SR on bacterial pneumonia caused by Streptococcus pneumoniae, we conducted a histopathological analysis by hematoxylin-eosin staining in a Streptococcus pneumoniae-infected mouse model. As shown in Figure 3, compared with those of the DMSO group, pathological results of the ES and SR groups showed that after ES and SR treatment, exudation and inflammatory cell infiltration were significantly reduced. The levels of IL-6 and TNF-α in BAL fluid also indicate the same results. Our results validate the good effects of ES and SR in the treatment of pneumonia. 3.2. Physical and Chemical Properties of ES and SR The results described above drew our attention to the specific mechanisms of ES and SR in the treatment of pneumonia. First, to clearly distinguish the physical and chemical properties of ES and SR, we used 6 specific quantitative indicators in TCMSP data to reflect the molecular characteristics of the drugs: oral bioavailability (OB), druglikeness (DL), molecular weight (MW), the number of donor atoms for H-bonds (nHDon), the number of acceptor atoms for H-bonds (nHAcc), and the Moriguchi octanol–water partition coeff. (log P). The OB and DL represent the pharmacological properties of the drug. As shown in Table 1, ES and SR are very different, and they are completely independent drugs. 3.3. Molecular Sets of ES and SR Furthermore, we screened the molecular sets of the two drugs by OB ≥ 30% and DL ≥ 0.18. ES contains a total of 25 molecules, and SR contains a total of 37 molecules, as shown in Table 2. It is worth noting that although psi-ephedrine and ephedrine have higher OB values, the DL values are only 0.03. However, they are the main alkaloids in ES [23], and these two molecules are even regarded as the main identification indicators of ES in the Chinese Pharmacopoeia. Considering the potential pharmacological effects of these two molecules, we still included these two molecules as the main molecular components of ES. Baicalin has a very high DL value (0.77), but its OB value is only 29.53. Similarly, based on the Chinese Pharmacopoeia and the possible substantial pharmacological effects of this molecule [24], we still regard baicalin as the main molecular component of SR. 3.4. Differentially Expressed Genes in Pneumonia The differentially expressed genes of 20 normal children and 152 children with CAP are in the supplementary file (Available here). In Figure 4, the first 50 differentially expressed genes are shown. 3.5. Active Molecules of ES and SR To further clarify the molecules involved in the interaction between these two drugs and pneumonia, we constructed a “drug-molecule-target-disease” network, as shown in Figure 5. In the ES network, we found that ES contains a total of 8 molecules that can interact with pneumonia-related targets: ephedrine, pseudoephedrine, herbacetin, kaempferol, quercetin, luteolin, stigmasterol, and naringenin. As mentioned earlier, ephedrine and psi-ephedrine, sympathetic amines with unique effects and an indirect mechanism of action, have a unique effect among sympathetic drugs, such as phenylephrine [25]; they are the two main components of ES and are usually used to constrict blood vessels [26] and treat colds [27]. Herbacetin is a natural flavonoid [28] and has been shown to have antioxidant, anticancer, and anti-inflammatory effects [29]. Kaempferol also has anticancer [30] and anti-inflammatory [31] effects. Quercetin has many functions, including regulating blood pressure [32], mediating anticancer effects [33], and treating inflammation and pain [34]. Luteolin has also been reported to have good anti-inflammatory effects [35]. Stigmasterol, a phytosterol, has cholesterol-lowering activity [36] and is valued as an anti-osteoarthritic agent [37]. Naringenin is a potential immunomodulator in therapeutics [38]. Coincidentally, in the SR network, we also found that eight molecules played a major role in the alleviation of pneumonia. They are wogonin, acacetin, baicalein, 5,7,4′-trihydroxy-8-methoxyflavone, neobaicalein, norwogonin, stigmasterol, and moslosooflavone. Baicalein is the main compound of SR. It inhibits apoptosis and autophagy [39] and protects nerves [40]. Wogonin has strong antitumor activity [41]. Acacetin has antioxidative and anti-inflammatory effects [42] as well as protective effects on cerebral blood vessels [43]. 5,7,4′-Trihydroxy-8-methoxyflavone can be used to treat influenza and its potential complications [44]. Neobaicalein has anticancer effects [45]. Norwogonin has antibacterial [46] and antidiabetic [47] activity. Moslosooflavone may have antihypoxia activity [48] and antivirus [49] effects. It is worth noting that stigmasterol is present in both ES and SR, and the intersection of this active ingredient may suggest that ES and SR also have a synergistic effect to some extent. The above ES and SR ingredients are flavonoids, except for stigmasterol, ephedrine, and psi-ephedrine. It has been proven that the main active molecules of ES and SR are mostly anti-inflammatory, antibacterial, or antiviral. However, we believe that ES and SR may act on different pathways. 3.6. GO-BP and KEGG Enrichment Analysis In addition to the drug components, the above research also provided information on 19 Ephedra and 8 Scutellaria targets in pneumonia. To further explain the biological functions corresponding to the targets, GO-BP and KEGG functions were used to enrich them. The results are shown in Figure 6. The GO-BP enrichment results suggest that ES can regulate neutrophil activation, the multiorganism process, the response to alkaloids, and others. Additionally, SR can regulate neutrophil activation, neutrophil degranulation, neutrophil activation involved in the immune response, and others. Regardless of the disease pathway, the KEGG enrichment results suggest that ES plays a therapeutic role through the NF-κB and apoptosis signaling pathways, while SR acts mainly through the IL-17 signaling pathway. NF-κB is considered to be a central regulator of the inflammatory process and an important participant in innate and adaptive immune responses [50]. It also plays a key role in regulating the expression of hundreds of immune-related genes, especially those encoding proinflammatory factors, chemokines, and other genes important for the development of the immune system [51]. Apoptosis usually occurs during development and aging and is an in vivo homeostasis mechanism for maintaining the number of cells in tissue [52]. The dysfunction of apoptosis leads to the release of a large number of proinflammatory factors, such as IL-1, IL-6, and IL-12, and it increases the immune burden on phagocytic cells. Excessive apoptosis of alveolar epithelial cells is an important mechanism of lung injury [53]. Therefore, it is necessary to maintain apoptosis in a dynamic balance and control excessive and abnormal apoptosis [54]. As a characteristic cytokine secreted by TH17 cells, IL-17 plays an important role in autoimmune diseases and immune-inflammatory damage diseases. There are 6 cytokines in the IL-17 family: IL-17A, IL-17B, IL-17C, IL-17D, IL-17E (IL-25), and IL-17F. Among them, IL-17A has been the most studied and is usually directly referred to as IL-17 [55]; it can induce a variety of proinflammatory factors, including IL-6, IL-1β, and TNF-α [56]. In particular, IL-6 can further promote the differentiation and activation of TH17 cells through positive feedback, forming a cytokine storm and aggravating inflammation [57]. We aimed to verify how ES and SR work on these three pathways. 3.7. PPI Network As the executors of cellular activities and functions, proteins do not exist independently. The interactions between proteins play an important role in each stage of life and maintain the steady state of the internal environment. To analyze the interaction between ES and SR target proteins, a PPI network of target proteins was constructed, as shown in Figure 7. We labeled NF-κB-related, apoptosis-related, and IL-17-related proteins in the figure for further verification. 3.8. Molecular Docking Above, we proved that the 8 active ingredients of ES may play a role in treating pneumonia by targeting the NF-κB pathway and the apoptosis pathway, and the 8 active ingredients of SR may play a role in treating pneumonia by targeting the IL-17 signaling pathway. However, these data were not sufficient to verify our results. We used the main target proteins of the NF-κB pathway, apoptosis pathway, and IL-17 signaling pathway in the PPI network, including PLAU, CD40LG, BLC2L1, CASP7, MMP9, CXCL8, and MAPK14, for verification. As shown in Figure 8, all components could be successfully docked with the target protein. In conclusion, our study proved that LAU, CD40LG, BLC2L1, CASP7, MMP9, CXCL8, and MAPK14 are the main targets of ES and SR. 4. Discussion Pneumonia is a serious global health problem. Antibiotics, vaccines, bacteriophages, and antimicrobial peptides are all considered to be treatments for bacterial pneumonia, but they are not perfect [58]. Chinese medicine is a traditional therapy that has been used in China for thousands of years and has the characteristics of multisystem and multitarget treatment. Due to the incomplete knowledge, research on traditional Chinese medicine is limited to the molecules contained in medicinal materials. It is believed that traditional Chinese medicinal materials are collections of multiple molecules. There are few studies on the mechanisms and targets of traditional Chinese medicines used for the treatment of pneumonia. In this study, we first put forward the theory of treating the same disease in different ways in traditional Chinese medicine. To prove this theory and investigate the compound structures of ES and SR in more detail, we used a database constructed by previous researchers [16] and obtained differentially expressed genes in patients with pneumonia from the GEO database. Based on the network pharmacology method, the specific mechanisms of the two traditional Chinese medicines in the treatment of pneumonia were studied to clarify the four types of qi in Chinese medicine and guide clinical treatment. In animal experiments, the alleviation of the effects of ES and SR, two traditional Chinese medicines, on pneumonia was proven. Then, we used OB ≥ 30% and DL ≥ 0.18 to thoroughly investigate the specific molecular components of ES and SR. Through the GEO database, information on differentially expressed genes associated with pneumonia was found. Based on the intersections of molecular target genes and differentially expressed genes associated with pneumonia, we believe that ES and SR have 8 effective components that can act on pneumonia. After GO-BP and KEGG enrichment of related genes, we found that ES can treat pneumonia through NF-κB and apoptosis and ES can play a therapeutic role through the IL-17 signaling pathway. Furthermore, we used molecular docking to verify the results and found that ES can regulate the NF-κB signaling pathway-related proteins PLAU, CD40LG, BLC2L1, and CXCL8. In addition, it can regulate the BLC2L1 (also related to NF-κB) and CASP7 proteins related to the apoptosis pathway. SR can regulate the MMP9, CXCL8, and MAPK14 proteins related to the IL-17 signaling pathway. In summary, we reached the following conclusions:ES and SR can both treat pneumonia in vivo. The active ingredients of ES for pneumonia are ephedrine, psi-ephedrine, herbacetin, kaempferol, quercetin, luteolin, stigmasterol, and naringenin. The active ingredients of SR for pneumonia are wogonin, acacetin, baicalein, 5,7,4′-trihydroxy-8-methoxyflavone, neobaicalein, norwogonin, stigmasterol, and moslosooflavone. ES plays a therapeutic role through the NF-κB and apoptosis signaling pathways, and SR plays a therapeutic role through the IL-17 signaling pathway. The eight main molecules of ES exerted a marked effect in treating pneumonia by targeting the NF-κB and apoptosis pathways through the PLAU, CD40LG, BLC2L1, CASP7, and CXCL8 proteins. The eight main components of SR can treat pneumonia by targeting the IL-17 signaling pathway though the CXCL8, MAPK14, and MMP9 proteins, as shown in Figure 9. Most importantly, ES, as a representative warm medicine, and SR, as a representative cold medicine, can both treat pneumonia. From another perspective, our ancestors found that in food preparation, labor, and the struggle with nature, they could use animal skins, bark bags, hot stones, or sandy soil as part of the heat for heating. Heating could eliminate some pain and gradually lead to the development of hot ironing and moxibustion. When using stone tools to work, it was found that after puncturing one part of the body, the pain in other parts of the body could be relieved, thereby creating a method of treating pain with vermiculite and bone needles. The consumption of certain animals and plants has the effect of reducing or eliminating disease, which is the origin of Chinese medicine. As humans evolved, they began to purposefully search for drugs and methods to prevent and treat diseases and developed primitive Chinese medicine. Later, with further development, traditional Chinese medicine was continuously improved by the Chinese people in terms of theory and methods. As shown in Figure 10, these developments gradually led to the current medicines and system. However, the holistic concept holds that human beings, nature, and society are a whole. Dialectical treatment emphasizes individualized treatment for each person. It also emphasizes the prevention-oriented concept of treating the disease and holds that disease resistance can be improved through emotional adjustment, moderate work and rest, a reasonable diet, and regular routines to achieve health and disease prevention. The four qi theory of Chinese medicine in this study belongs to the dialectical governance theory. These theories and practices greatly protected the health of ancient Chinese people and continue to protect health to this day. There is no doubt that most of these theories are related to philosophy, and only the Chinese people, with the cultural heritage passed down from their ancestors, can understand these ideas without further learning. To date, traditional Chinese medicine has been regarded as a complementary and alternative medicine, and the data support this view. However, looking at the history of modern medicine, from bloodletting therapy to the use of antibiotics and the sequencing of the human genome, the degree of human understanding of the disease is closely related to developments in the understanding of the human body. The development of modern medicine is a history of scientific and technological progress. Modern medicine continues to push the limits of technology. Organ, tissue, and cell transplants, test-tube babies, laser medicine, and other developments have all contributed to protecting human health. Modern medicine is undoubtedly mainstream medicine in modern society. However, we should not forget the traditional medicine that has treated countless people just because better treatments are available. Modern medicine also has many unsolved problems, such as AIDS, Alzheimer's disease, and even diabetes. No one can guarantee that traditional Chinese medicine will not make some breakthroughs in these unsolved fields, similar to Tu [59]. The potential utility of Chinese herbs in clinical practice in the future includes replacing or reducing the use of antibiotics [60, 61], reducing the overuse of hormone drugs [62], antivirus activity [63], antitumor activity [64], improving immunity [65], and others. After all, humans know too little about the world. In short, in this study, we take ES and SR as examples and use a combination of network pharmacology and transcriptomics and experimental results to prove the TCM theory of treating the same disease with different treatments. We think it is very important to explore the theory and continue the practice of TCM. Acknowledgments This work was supported by the National Key Research and Development Program of China (2017YFC1703202), the Jilin Scientific and Technological of Chinese Medicine Program (2019023), the Inheritance and Innovation of Chinese Medicine of “Millions of Standouts” Project (the Project of Qihuang), the Inheritance Workroom of the Chinese Medicine Master Wang Lie, and the Jilin Scientific and Technological Program of Sanitation and Population Control (2018J106). Data Availability The data used to support the findings of this study are included within the supplementary information file. Conflicts of Interest The authors declare no conflicts of interest. Authors' Contributions Liping Sun and Dandan Wang contributed equally to this work. Liping Sun and Dandan Wang were responsible for experiments and wrote the article. Yan Xu and Wenxiu Qi made the figures and assisted in the experiments. Liping Sun and Yanbo Wang discussed and edited the content of the research article. All authors have read and approved the manuscript. Supplementary Materials Supplementary Materials The differentially expressed genes of 20 normal children and 152 children with CAP. Click here for additional data file. Figure 1 Disease development and treatment in Chinese medicine. Figure 2 Research schematic. Figure 3 Pathological sections from mice treated with ES and SR. (a) is the control group, (b) is the model group, (c) is the DMSO treatment group, (d) is the ES treatment group, and (e) is the SR treatment group. (f) and (g) are the expression levels of IL-6 and TNF-α, respectively. ∗∗p ≤ 0.01. Figure 4 Top 50 differentially expressed genes between healthy and CAP children. Lavender represents high expression, and the green represents low expression. Figure 5 “Drug-Molecule-Target-Disease” network. Yellow represents drugs, blue represents molecules, green represents diseases, and red represents targets. Figure 6 GO-BP and KEGG enrichment results for ES and SR. (a) KEGG enrichment result for ES, (b) KEGG enrichment result for SR, (c) GO-BP enrichment result for ES, and (d) GO-BP enrichment result for SR. Figure 7 PPI networks of ES and SR. (a) The network for ES; red represents proteins related to the NF-κB pathway, and blue represents proteins related to apoptosis. (b) The networks for SR; green represents proteins related to the IL-17 signaling pathway. Figure 8 Molecular docking of ES and SR to the targets. (a) ES and (b) SR. The numbers in the table represent the affinity, and an affinity less than 0 indicates successful docking. Figure 9 Pathways of ES and SR. (a) is the NF-κB signaling pathway, (b) is the apoptosis signaling pathway, and (c) is the IL-17 signaling pathway. Red is the targets of ES and SR. Figure 10 History of TCM development. Table 1 Physicochemical properties of Ephedra and Scutellaria. Herb n MW nHDon nHAcc log P OB DL ES 363 202.72 (100.40) 0.85 (1.51) 1.81 (2.28) 3.47 (2.72) 37.12 (19.11) 0.11 (0.17) SR 143 277.73 (106.36) 1.44 (1.92) 3.47 (3.21) 4.10 (3.33) 31.41 (18.67) 0.23 (0.21) The values in the table are the mean (SD). Table 2 Molecular sets of ES and SR after screening. Molid Compound OB DL Structure ES1 MOL010788 Leucopelargonidin 57.97 0.24 ES2 MOL002823 Herbacetin 36.07 0.27 ES3 MOL010489 Resivit 30.84 0.27 ES4 MOL000422 Kaempferol 41.88 0.24 ES5 MOL004798 Delphinidin 40.63 0.28 ES6 MOL000098 Quercetin 46.43 0.28 ES7 MOL000006 Luteolin 36.16 0.25 ES8 MOL000358 Beta-sitosterol 36.91 0.75 ES9 MOL000449 Stigmasterol 43.83 0.76 ES10 MOL000492 (+)-catechin 54.83 0.24 ES11 MOL001494 Mandenol 42 0.19 ES12 MOL001506 Supraene 33.55 0.42 ES13 MOL001755 24-Ethylcholest-4-en-3-one 36.08 0.76 ES14 MOL001771 Poriferast-5-en-3beta-ol 36.91 0.75 ES15 MOL002881 Diosmetin 31.14 0.27 ES16 MOL004328 Naringenin 59.29 0.21 ES17 MOL004576 Taxifolin 57.84 0.27 ES18 MOL005043 Campest-5-en-3beta-ol 37.58 0.71 ES19 MOL005190 Eriodictyol 71.79 0.24 ES20 MOL005573 Genkwanin 37.13 0.24 ES21 MOL005842 Pectolinarigenin 41.17 0.3 ES22 MOL007214 (+)-Leucocyanidin 37.61 0.27 ES23 MOL011319 Truflex OBP 43.74 0.24 ES24 MOL006637 Psi-ephedrine 52.25 0.03 ES25 MOL006594 Ephedrine 43.35 0.03 SR1 MOL001689 Acacetin 34.97 0.24 SR2 MOL000173 Wogonin 30.68 0.23 SR3 MOL000228 (2R)-7-Hydroxy-5-methoxy-2-phenylchroman-4-one 55.23 0.2 SR4 MOL002714 Baicalein 33.52 0.21 SR5 MOL002908 5,8,2′-Trihydroxy-7-methoxyflavone 37.01 0.27 SR6 MOL002909 5,7,2,5-Tetrahydroxy-8,6-dimethoxyflavone 33.82 0.45 SR7 MOL002910 Carthamidin 41.15 0.24 SR8 MOL002911 2,6,2′,4′-Tetrahydroxy-6′-methoxychaleone 69.04 0.22 SR9 MOL002913 Dihydrobaicalin_qt 40.04 0.21 SR10 MOL002914 Eriodyctiol (flavanone) 41.35 0.24 SR11 MOL002915 Salvigenin 49.07 0.33 SR12 MOL002917 5,2′,6′-Trihydroxy-7,8-dimethoxyflavone 45.05 0.33 SR13 MOL002925 5,7,2′,6′-Tetrahydroxyflavone 37.01 0.24 SR14 MOL002926 Dihydrooroxylin A 38.72 0.23 SR15 MOL002927 Skullcapflavone II 69.51 0.44 SR16 MOL002928 Oroxylin a 41.37 0.23 SR17 MOL002932 Panicolin 76.26 0.29 SR18 MOL002933 5,7,4′-Trihydroxy-8-methoxyflavone 36.56 0.27 SR19 MOL002934 Neobaicalein 104.34 0.44 SR20 MOL002937 Dihydrooroxylin 66.06 0.23 SR21 MOL000358 Beta-sitosterol 36.91 0.75 SR22 MOL000359 Sitosterol 36.91 0.75 SR23 MOL000525 Norwogonin 39.4 0.21 SR24 MOL000552 5,2′-Dihydroxy-6,7,8-trimethoxyflavone 31.71 0.35 SR25 MOL000073 Ent-epicatechin 48.96 0.24 SR26 MOL000449 Stigmasterol 43.83 0.76 SR27 MOL001458 Coptisine 30.67 0.86 SR28 MOL001490 Bis [(2S)-2-ethylhexyl] benzene-1,2-dicarboxylate 43.59 0.35 SR29 MOL001506 Supraene 33.55 0.42 SR30 MOL002879 Diop 43.59 0.39 SR31 MOL002897 Epiberberine 43.09 0.78 SR32 MOL008206 Moslosooflavone 44.09 0.25 SR33 MOL010415 11,13-Eicosadienoic acid, methyl ester 39.28 0.23 SR34 MOL012245 5,7,4′-Trihydroxy-6-methoxyflavanone 36.63 0.27 SR35 MOL012246 5,7,4′-Trihydroxy-8-methoxyflavanone 74.24 0.26 SR36 MOL012266 Rivularin 37.94 0.37 SR37 MOL002935 Baicalin 29.53 0.77 ==== Refs 1 Michaud C. M. Murray C. J. Bloom B. R. Burden of disease-implications for future research JAMA 2001 285 5 535 539 10.1001/jama.285.5.535 2-s2.0-0035819481 11176854 2 Rudan I. Boschi-Pinto C. Biloglav Z. Mulholland K. Campbell H. Epidemiology and etiology of childhood pneumonia Bulletin of the World Health Organization 2008 86 5 408 416 10.2471/blt.07.048769 2-s2.0-43749088498 18545744 3 Quinton L. J. Walkey A. J. Mizgerd J. P. Integrative physiology of pneumonia Physiological Reviews 2018 98 3 1417 1464 10.1152/physrev.00032.2017 2-s2.0-85055654433 29767563 4 Campanini-Salinas J. Andrades-Lagos J. Mella-Raipan J. Vasquez-Velasquez D. Novel classes of antibacterial drugs in clinical development, a hope in a post-antibiotic era Current Topics in Medicinal Chemistry 2018 18 14 1188 1202 10.2174/1568026618666180816162846 2-s2.0-85055618642 30117393 5 Jee Y. Carlson J. Rafai E. Antimicrobial resistance: a threat to global health The Lancet Infectious Diseases 2018 18 9 939 940 10.1016/S1473-3099(18)30471-7 2-s2.0-85051922351 30152350 6 Qiu J. When the East meets the West: the future of traditional Chinese medicine in the 21st century National Science Review 2015 2 3 377 380 10.1093/nsr/nwv049 2-s2.0-84954144793 7 Lu A.-P. Jia H.-W. Xiao C. Lu Q.-P. Theory of traditional Chinese medicine and therapeutic method of diseases World Journal of Gastroenterology 2004 10 13 10.1007/bf02836394 8 Jiang W.-Y. Therapeutic wisdom in traditional Chinese medicine: a perspective from modern science Trends in Pharmacological Sciences 2005 26 11 558 563 10.1016/j.tips.2005.09.006 2-s2.0-27144432852 16185775 9 Jin R. Zhang B. Analysis on complex characteristics of traditional Chinese medicine property theory Zhongguo Zhong Yao Za Zhi 2012 37 21 3340 3343 23397741 10 Wu G.-S. Li H.-K. Zhang W.-D. Metabolomics and its application in the treatment of coronary heart disease with traditional Chinese medicine Chinese Journal of Natural Medicines 2019 17 5 321 330 10.1016/s1875-5364(19)30037-8 2-s2.0-85066414231 31171266 11 Zhao S. Liu Z. Wang M. Anti-inflammatory effects of Zhishi and Zhiqiao revealed by network pharmacology integrated with molecular mechanism and metabolomics studies Phytomedicine 2018 50 61 72 10.1016/j.phymed.2018.09.184 2-s2.0-85054299888 30466993 12 Peng Z. Li J. Yang L. Li Y. Tian Y. Li S. Integration of transcriptomics, proteomics, metabolomics and systems pharmacology data to reveal the therapeutic mechanism underlying Chinese herbal Bufei Yishen formula for the treatment of chronic obstructive pulmonary disease Molecular Medicine Reports 2018 17 4 5247 5257 10.3892/mmr.2018.8480 2-s2.0-85043259934 29393428 13 He L. Fang M. Chen L. Transcriptome analysis of blood stasis syndrome in subjects with hypertension Journal of Traditional Chinese Medicine 2016 36 2 173 180 10.1016/s0254-6272(16)30024-3 27400471 14 Xianjun F. Mervin L. H. Li X. Toward understanding the cold, hot, and neutral nature of Chinese medicines using in silico mode-of-action analysis Journal of Chemical Information and Modeling 2017 57 3 468 483 10.1021/acs.jcim.6b00725 2-s2.0-85025099639 28257573 15 Yu W. J. Shen Z. Y. From “different patterns in the same disease” to “analogous patterns in the same disease” Zhongguo Zhong Xi Yi Jie He Za Zhi 2014 34 1 9 12 24520778 16 Ru J. Li P. Wang J. TCMSP: a database of systems pharmacology for drug discovery from herbal medicines Journal of Cheminformatics 2014 6 p. 13 10.1186/1758-2946-6-13 2-s2.0-84899981355 17 Yamashita F. Hashida M. In silico approaches for predicting ADME properties of drugs Drug Metabolism and Pharmacokinetics 2004 19 5 327 338 10.2133/dmpk.19.327 2-s2.0-16644369555 15548844 18 Yao Y. Zhang X. Wang Z. Deciphering the combination principles of traditional Chinese medicine from a systems pharmacology perspective based on Ma-huang Decoction Journal of Ethnopharmacology 2013 150 2 619 638 10.1016/j.jep.2013.09.018 2-s2.0-84887440094 24064232 19 Barrett T. Wilhite S. E. Ledoux P. NCBI GEO: archive for functional genomics data sets—update Nucleic Acids Research 2013 41 Database issue D991 D995 10.1093/nar/gks1193 2-s2.0-84874271270 23193258 20 Lee S. G. Hur J. U. Kim Y. S. A graph-theoretic modeling on GO space for biological interpretation of gene clusters Bioinformatics 2004 20 3 381 388 10.1093/bioinformatics/btg420 2-s2.0-1342330530 14960465 21 Lee S. Lee K. H. Song M. Lee D. Building the process-drug-side effect network to discover the relationship between biological processes and side effects BMC Bioinformatics 2011 12 2 10.1186/1471-2105-12-s2-s2 22 Yu G. Wang L.-G. Han Y. He Q.-Y. ClusterProfiler: an R package for comparing biological themes among gene clusters OMICS: A Journal of Integrative Biology 2012 16 5 284 287 10.1089/omi.2011.0118 2-s2.0-84860718683 22455463 23 Tong J. Y. Chao J. Dai Y. T. Establish quality evaluation system for standard Ephedrae Herba decoction Zhongguo Zhong Yao Za Zhi 2017 42 5 823 829 28994520 24 Luo J. Dong B. Wang K. Baicalin inhibits biofilm formation, attenuates the quorum sensing-controlled virulence and enhances Pseudomonas aeruginosa clearance in a mouse peritoneal implant infection model PLoS One 2017 12 4 e0176883 10.1371/journal.pone.0176883 2-s2.0-85018273523 25 Radiloff D. Zhao Y. Boico A. Anti-hypotensive treatment and endothelin blockade synergistically antagonize exercise fatigue in rats under simulated high altitude PLoS One 2014 9 6 e99309 10.1371/journal.pone.0099309 2-s2.0-84903529792 26 Laccourreye O. Werner A. Giroud J.-P. Couloigner V. Bonfils P. Bondon-Guitton E. Benefits, limits and danger of ephedrine and pseudoephedrine as nasal decongestants European Annals of Otorhinolaryngology, Head and Neck Diseases 2015 132 1 31 34 10.1016/j.anorl.2014.11.001 2-s2.0-84922927740 27 Zhang Y. Mallefet P. Time-to-onset of cold and flu symptom relief: a randomized, double-blind, placebo-controlled pilot study for a multi-symptom combination product International Journal of Clinical Pharmacology and Therapeutics 2018 56 12 604 611 10.5414/cp203259 2-s2.0-85057008338 30220290 28 Struijs K. Vincken J.-P. Doeswijk T. G. Voragen A. G. J. Gruppen H. The chain length of lignan macromolecule from flaxseed hulls is determined by the incorporation of coumaric acid glucosides and ferulic acid glucosides Phytochemistry 2009 70 2 262 269 10.1016/j.phytochem.2008.12.015 2-s2.0-60249102799 19155025 29 Li L. Fan P. Chou H. Li J. Wang K. Li H. Herbacetin suppressed MMP9 mediated angiogenesis of malignant melanoma through blocking EGFR-ERK/AKT signaling pathway Biochimie 2019 162 198 207 10.1016/j.biochi.2019.05.003 2-s2.0-85065495186 31075281 30 Imran M. Salehi B. Sharifi-Rad J. Kaempferol: a key emphasis to its anticancer potential Molecules 2019 24 12 10.3390/molecules24122277 2-s2.0-85068472007 31 Devi K. P. Malar D. S. Nabavi S. F. Kaempferol and inflammation: from chemistry to medicine Pharmacological Research 2015 99 1 10 10.1016/j.phrs.2015.05.002 2-s2.0-84930203898 25982933 32 Marunaka Y. Marunaka R. Sun H. Actions of quercetin, a polyphenol, on blood pressure Molecules 2017 22 2 10.3390/molecules22020209 2-s2.0-85013997408 33 Reyes-Farias M. Carrasco-Pozo C. The anti-cancer effect of quercetin: molecular implications in cancer metabolism International Journal of Molecular Sciences 2019 20 13 10.3390/ijms20133177 34 Carullo G. Cappello A. R. Frattaruolo L. Badolato M. Armentano B. Aiello F. Quercetin and derivatives: useful tools in inflammation and pain management Future Medicinal Chemistry 2017 9 1 79 93 10.4155/fmc-2016-0186 2-s2.0-85008144018 27995808 35 Aziz N. Kim M.-Y. Cho J. Y. Anti-inflammatory effects of luteolin: a review of in vitro, in vivo, and in silico studies Journal of Ethnopharmacology 2018 225 342 358 10.1016/j.jep.2018.05.019 2-s2.0-85047256115 29801717 36 Wang S. Ye K. Shu T. Tang X. Wang X. J. Liu S. Enhancement of galloylation efficacy of stigmasterol and β -sitosterol followed by evaluation of cholesterol-reducing activity Journal of Agricultural and Food Chemistry 2019 67 11 3179 3187 10.1021/acs.jafc.8b06983 2-s2.0-85063124308 30827096 37 Gabay O. Sanchez C. Salvat C. Stigmasterol: a phytosterol with potential anti-osteoarthritic properties Osteoarthritis and Cartilage 2010 18 1 106 116 10.1016/j.joca.2009.08.019 2-s2.0-72449191694 19786147 38 Zeng W. Jin L. Zhang F. Zhang C. Liang W. Naringenin as a potential immunomodulator in therapeutics Pharmacological Research 2018 135 122 126 10.1016/j.phrs.2018.08.002 2-s2.0-85051132914 30081177 39 Yan W. Ma X. Zhao X. Zhang S. Baicalein induces apoptosis and autophagy of breast cancer cells via inhibiting PI3K/AKT pathway in vivo and vitro Drug Design, Development and Therapy 2018 12 3961 3972 10.2147/dddt.s181939 2-s2.0-85057818376 40 Sowndhararajan K. Deepa P. Kim M. Park S. J. Kim S. Baicalein as a potent neuroprotective agent: a review Biomedicine & Pharmacotherapy 2017 95 1021 1032 10.1016/j.biopha.2017.08.135 2-s2.0-85029318384 28922719 41 Huynh D. L. Sharma N. Kumar Singh A. Anti-tumor activity of wogonin, an extract from Scutellaria baicalensis, through regulating different signaling pathways Chinese Journal of Natural Medicines 2017 15 1 15 40 10.1016/s1875-5364(17)30005-5 2-s2.0-85014106125 28259249 42 Sun L.-C. Zhang H.-B. Gu C.-D. Protective effect of acacetin on sepsis-induced acute lung injury via its anti-inflammatory and antioxidative activity Archives of Pharmacal Research 2018 41 12 1199 1210 10.1007/s12272-017-0991-1 2-s2.0-85038097622 29243040 43 Guo J. Shi S. Wang H. Q. Acacetin protects against cerebral ischemia-reperfusion injury via the NLRP3 signaling pathway Neural Regeneration Research 2019 14 4 605 612 10.4103/1673-5374.247465 2-s2.0-85059975606 30632500 44 Uchide N. Toyoda H. Antioxidant therapy as a potential approach to severe influenza-associated complications Molecules 2011 16 3 2032 2052 10.3390/molecules16032032 2-s2.0-79953068333 21358592 45 Jia D. Chen X. Cao Y. On-line comprehensive two-dimensional HepG2 cell membrane chromatographic analysis system for charactering anti-hepatoma components from rat serum after oral administration of radix scutellariae: a strategy for rapid screening active compounds in vivo Journal of Pharmaceutical and Biomedical Analysis 2016 118 27 33 10.1016/j.jpba.2015.10.013 2-s2.0-84945266040 26512996 46 Miyasaki Y. Rabenstein J. D. Rhea J. Isolation and characterization of antimicrobial compounds in plant extracts against multidrug-resistant Acinetobacter baumannii PLoS One 2013 8 4 e61594 10.1371/journal.pone.0061594 2-s2.0-84876453756 47 Ahmed Q. U. Sarian M. N. Mat So’ad S. Z. Methylation and acetylation enhanced the antidiabetic activity of some selected flavonoids: in vitro, molecular modelling and structure activity relationship-based study Biomolecules 2018 8 4 10.3390/biom8040149 2-s2.0-85056724544 48 Jing L. L. He L. Fan P. C. Jia Z. P. Ma H. P. Chemical constituents with anti-hypoxia activity from saussurea involucrata Zhong Yao Cai 2015 38 1 89 92 26214875 49 Kwon B. E. Song J. H. Song H. H. Antiviral activity of oroxylin A against coxsackievirus B3 alleviates virus-induced acute pancreatic damage in mice PLoS One 2016 11 5 e0155784 10.1371/journal.pone.0155784 2-s2.0-84973629976 50 DiDonato J. A. Mercurio F. Karin M. NF-κ B and the link between inflammation and cancer Immunological Reviews 2012 246 1 379 400 10.1111/j.1600-065x.2012.01099.x 2-s2.0-84858718448 22435567 51 Mitchell J. P. Carmody R. J. NF-κ B and the transcriptional control of inflammation International Review of Cell and Molecular Biology 2018 335 41 84 10.1016/bs.ircmb.2017.07.007 2-s2.0-85028875635 29305014 52 Elmore S. Apoptosis: a review of programmed cell death Toxicologic Pathology 2007 35 4 495 516 10.1080/01926230701320337 2-s2.0-34250308322 17562483 53 Hagimoto N. Kuwano K. Hara N. The roles of apoptosis in lung injury Nihon Kokyuki Gakkai Zasshi 2002 40 5 343 349 12166251 54 Kolb J. P. Oguin T. H. III Oberst A. Martinez J. Programmed cell death and inflammation: winter is coming Trends in Immunology 2017 38 10 705 718 10.1016/j.it.2017.06.009 2-s2.0-85024897312 28734635 55 Monin L. Gaffen S. L. Interleukin 17 family cytokines: signaling mechanisms, biological activities, and therapeutic implications Cold Spring Harbor Perspectives in Biology 2018 10 4 10.1101/cshperspect.a028522 2-s2.0-85045007409 56 Veldhoen M. Interleukin 17 is a chief orchestrator of immunity Nature Immunology 2017 18 6 612 621 10.1038/ni.3742 2-s2.0-85019909348 28518156 57 Ogura H. Murakami M. Okuyama Y. Interleukin-17 promotes autoimmunity by triggering a positive-feedback loop via interleukin-6 induction Immunity 2008 29 4 628 636 10.1016/j.immuni.2008.07.018 2-s2.0-55049118394 18848474 58 Manoharan A. Jayaraman R. Pneumococcal vaccines Indian Journal of Medical Microbiology 2018 36 4 465 474 10.4103/ijmm.ijmm_18_442 2-s2.0-85063263969 30880692 59 Tu Y. Artemisinin-A gift from traditional Chinese medicine to the world (nobel lecture) Angewandte Chemie International Edition 2016 55 35 10210 10226 10.1002/anie.201601967 2-s2.0-84982190036 27488942 60 Xu Y. Wang Y. Guo Y. Cortex cercis chinensis granules attenuate Streptococcus pneumoniae virulence by targeting pneumolysin Evidence-Based Complementary and Alternative Medicine: eCAM 2020 2020 7 8537026 61 Xu Y. Wei L. Wang Y. Inhibitory effect of the traditional Chinese medicine Ephedra sinica granules on Streptococcus pneumoniae pneumolysin Biological and Pharmaceutical Bulletin 2020 43 6 994 999 10.1248/bpb.b20-00034 32475921 62 Kou M. J. Ding X. F. Chen J. X. Liu Y. Liu Y. Y. Traditional Chinese medicine combined with hormone therapy to treat premature ovarian failure: a meta-analysis of randomized controlled trials African Journal of Traditional, Complementary, and Alternative Medicines: AJTCAM 2016 13 5 160 169 63 Zhang Y. Lyu C. Fong S. Y. K. Evaluation of potential herb-drug interactions between oseltamivir and commonly used anti-influenza Chinese medicinal herbs Journal of Ethnopharmacology 2019 243 112097 10.1016/j.jep.2019.112097 2-s2.0-85069727252 64 Lam W. Jiang Z. Guan F. PHY906 (KD018), an adjuvant based on a 1800-year-old Chinese medicine, enhanced the anti-tumor activity of Sorafenib by changing the tumor microenvironment Scientific Reports 2015 5 p. 9384 10.1038/srep09384 2-s2.0-84925866848 25819872 65 Zhang M. M. Fu Z. T. Chen J. T. Immune regulation effect of Chinese medicine of invigorating spleen and kidney detoxification on simian immunodeficiency virus-infected rhesus macaque Zhongguo Zhong Yao Za Zhi=Zhongguo Zhongyao Zazhi=China Journal of Chinese Materia Medica 2017 42 11 2152 2158 28822162